查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
眼科臨床試驗市場規模、份額和趨勢分析報告：按產品、按階段、按適應症、按贊助商類型、按地區、細分市場預測，2023-2030 年
市場調查報告書
商品編碼
1301236

眼科臨床試驗市場規模、份額和趨勢分析報告：按產品、按階段、按適應症、按贊助商類型、按地區、細分市場預測，2023-2030 年

Ophthalmic Clinical Trials Market Size, Share & Trends Analysis Report By Product (Devices, Drugs), By Phase (Discovery Phase, Preclinical Phase, Clinical Phase), By Indication, By Sponsor Type, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

眼科臨床試驗市場增長和趨勢

GrandView Research, Inc.最新報告顯示，到2030年，全球眼科臨床試驗市場規模預計將達到25億美元，預測期內復合年增長率為6.6%。

技術的發展和對更有效的眼部疾病治療方法日益增長的需求正在推動眼科臨床試驗市場的快速擴張。製藥公司、醫療器械製造商和合同研究組織 (CRO) 是該領域的主要貢獻者。

青光眼、黃斑變性和糖尿病視網膜病變等眼部疾病患病率的上升正在推動該行業的發展。隨著全球人口老齡化和眼病變得更加普遍，眼科臨床試驗市場預計將進一步增長。此外，基因研究和個性化醫療的發展可能會刺激該領域的創新，從而為眼部疾病提供更專業、更有效的治療方法。

隨著眼科研究人員專注於開發和營銷新型眼科藥物，對臨床試驗的需求預計將會增加。此外，為滿足新興經濟體對罕見眼病未滿足的需求而採取的舉措預計將支持眼科臨床試驗市場的增長。例如，根據世界衛生組織（WHO）2021年10月發布的《視障者殘疾報告》，估計約有22億人患有分離視力或近視，其中至少有一半的病例是可以預防的在適當治療的幫助下。

COVID-19 大流行對眼科臨床試驗市場產生了重大影響。在臨床試驗方面，疫情推遲了新試驗的開始和患者入組。此外，多個臨床試驗中心被迫關閉，顯著減少了患者就診和數據收集。疫情加速了遠程和虛擬臨床試驗技術的部署，使正在進行的臨床試驗得以繼續，並開始新的臨床試驗。通過採用這些技術，緩解了大流行帶來的一些困難，例如旅行限制和社會隔離的需要。

眼科臨床試驗市場亮點

  • 2022年，醫藥板塊佔比最大，達75.5%。由於對各種眼部疾病的創新和有效藥物療法的需求不斷增長，該細分市場佔據了市場主導地位。
  • 在分析期間，青光眼細分市場預計將以 7.3% 的複合年增長率增長。主要公司之間加強合作和夥伴關係開發新型青光眼治療方法正在推動該領域的發展。
  • 2022 年，臨床階段細分市場以 79.4% 的銷售份額佔據市場主導地位。政府和私營公司為進行臨床試驗而增加的研發投資正在推動該行業的增長。
  • 2022年，該市場將由製藥/生物製藥公司主導，收入份額為41.8%。眼科臨床試驗的主要贊助商是製藥和生物製藥公司，他們擁有開發和商業化新療法的資源和知識。
  • 預計在分析期間，亞太地區的複合年增長率將達到 7.2%。這主要是由於想要參與臨床試驗的患者群體較多。此外，印度等新興市場臨床試驗的成本效益進一步吸引西方國家開展臨床研究，推動該地區眼科臨床試驗市場的增長。

目錄

第一章 調查方法和範圍

  • 市場細分和範圍
  • 區域範圍
  • 估計/預測時間表
  • 目的
  • 調查方法
  • 信息採購
  • 信息或數據分析
  • 市場形成和驗證
  • 型號詳情
  • 二級信息列表
  • 縮略語表

第二章執行摘要

  • 市場展望
  • 分部展望
  • 競爭考慮

3.眼科臨床試驗市場變量、趨勢和範圍

  • 市場譜系展望
    • 母公司市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場驅動力分析
    • 市場約束因素分析
  • 眼科臨床試驗市場分析工具
    • 行業分析-波特分析
    • PESTEL 分析
    • COVID-19 感染的影響分析

第四章眼科臨床試驗市場：產品評估和趨勢分析

  • 眼科臨床試驗市場，副產品：細分儀表板
  • 眼科臨床試驗市場，副產品：變異分析
    • 設備
    • 藥物

第五章眼科臨床試驗市場：適應症估計和趨勢分析

  • 眼科臨床試驗市場，按適應症：細分儀表板
  • 眼科臨床試驗市場，按適應症：變異分析
    • 黃斑變性
    • 青光眼
    • 乾眼症
    • 視網膜病變
    • 葡萄膜炎
    • 黃斑水腫
    • 瞼緣炎
    • 白內障
    • 視神經病變
    • 其他

第六章眼科臨床試驗市場：階段估計和趨勢分析

  • 眼科臨床試驗市場，按階段：細分儀表板
  • 眼科臨床試驗市場，按階段：變異分析
    • 發現階段
    • 臨床前階段
    • 臨床分期

第七章眼科臨床試驗市場：申辦者類型估計和趨勢分析

  • 眼保健臨床試驗市場，按贊助商類型：細分儀表板
  • 眼科臨床試驗市場，按贊助商類型：變異分析
    • 製藥/生物製藥公司
    • 醫療器械公司
    • 其他

第八章眼科臨床試驗市場：區域估計和趨勢分析

  • 2022 年和 2030 年區域市場份額分析
  • 區域市場儀表板
  • 全球區域市場快照
  • 北美
    • 2018-2030 年市場估計和預測（收入）
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 意大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 印度
    • 中國
    • 韓國
    • 澳大利亞
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 多邊環境協定
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 科威特

第9章 競爭格局

  • 市場進入者分類
    • 創新者
    • 市場領導者
    • 新興玩家
    • 2022 年公司市場份額分析
  • 公司簡介
    • Charles River Laboratories International, Inc
    • Laboratory Corporation of America Holdings
    • IQVIA
    • ICON Plc
    • Vial
    • Medpace
    • ProTrials Research, Inc.
    • Syneos Health
    • Worldwide Clinical Trials, Inc
    • ProRelix Services LLP.
Product Code: GVR-4-68040-085-8

Ophthalmic Clinical Trials Market Growth & Trends

The global ophthalmic clinical trials market size is expected to reach USD 2.5 billion by 2030 at a CAGR of 6.6% over the forecast period, according to a new report by Grand View Research, Inc. Technological developments and a rising need for more efficient eye disease treatments are driving the market for ophthalmology clinical trials to expand quickly. Pharmaceutical firms, medical equipment producers, and Contract Research Organizations (CROs) are a few of the major contributors to this sector.

The rising incidence of eye conditions, including glaucoma, macular degeneration, and diabetic retinopathy, is driving the industry. As the global population ages and eye illnesses become more common, the market for ophthalmology clinical trials is further anticipated to grow in the coming years. Additionally, developments in genetic research and personalized medicine are likely to spur innovation in this area, creating more specialized and efficient treatments for eye illnesses.

The demand for clinical trials will rise due to the increasing focus of ophthalmic researchers to develop and market novel ocular medicines. Furthermore, the initiatives adopted to fulfill the unmet needs in developing economies regarding rare ocular conditions are anticipated to support the growth of the ophthalmology clinical trials market. For instance, nearly 2.2 billion people are estimated to have separation or close-up vision impairment disorders, and of these, at least half, or 1 billion cases, can be avoided with the aid of appropriate treatment, according to the World Health Organization's October 2021 report on visually impaired people's impairment.

The COVID-19 pandemic has significantly impacted the ophthalmology clinical trials market. Clinical trials have been hampered by the epidemic, which has delayed the start of new trials and slowed patient enrollment. Additionally, several clinical study locations had to close, significantly reducing patient visits and data collecting. The epidemic has hastened the deployment of remote and virtual clinical trial technology, allowing for the continuation of ongoing trials and the start of new ones. Some of the difficulties brought on by the pandemic, including travel limitations and social seclusion requirements, have been mitigated partly by adopting these technologies.

Ophthalmic Clinical Trials Market Highlights

  • The drug segment accounted for the largest share of 75.5% in 2022. The segment dominated the market owing to the growing demand for innovative and efficient drug therapies for various eye ailments
  • The Glaucoma segment is expected to witness the highest CAGR of 7.3% during the analysis timeframe. The increase in collaboration and partnerships among the key players for developing novel glaucoma products spurs the segment's growth
  • The clinical phase segment dominated the market in 2022 with a revenue share of 79.4%. Increasing investments in R&D by the government, as well as private entities for the conduct of clinical studies, drives the segment's growth
  • The pharmaceutical/biopharmaceutical companies segment dominated the market in 2022 with a revenue share of 41.8%. The major sponsors of ophthalmology clinical trials are pharmaceutical and biopharmaceutical companies since they have the resources and knowledge to create and commercialize novel treatments
  • Asia Pacific is anticipated to register a lucrative CAGR of 7.2% during the analysis period. This is primarily due to a huge patient pool willing to undergo clinical trials. Furthermore, the cost-effective nature of clinical trials across developing economies such as India has further attracted Western countries to conduct clinical research, thereby boosting the region's growth in the ophthalmic clinical trials market

Table of contents

Chapter 1. Research Methodology And Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
    • 1.1.2. Product
    • 1.1.3. Indication
    • 1.1.4. Phase
    • 1.1.5. Sponsor Type
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Ophthalmic Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Partnerships Between CROs And Drug Development Companies To Boost The Market Growth
      • 3.2.1.2. Growing Research Funding Pertaining To Ocular Therapeutics Is Another Prominent Factor Supporting The Growth Of The Ophthalmic Clinical Trials Market.
      • 3.2.1.3. Technological Innovations Pertaining to Ophthalmic Research to Boost The Market Growth
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Low Barriers to Market Penetration Have Resulted In Pricing Pressure
      • 3.2.2.2. Challenges Related to Quality Control
  • 3.3. Ophthalmic Clinical Trials Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat Of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Ophthalmic Clinical Trials Market: Product Estimates & Trend Analysis

  • 4.1. Ophthalmic Clinical Trials Market, By Product: Segment Dashboard
  • 4.2. Ophthalmic Clinical Trials Market, By Product: Movement Analysis
  • 4.3. Ophthalmic Clinical Trials Market Estimates & Forecasts, By Product, 2018 - 2030
    • 4.3.1. Devices
      • 4.3.1.1. Devices Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
      • 4.3.1.2. Surgical & Diagnostics Devices
      • 4.3.1.2.1. Surgical & Diagnostics Devices Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
      • 4.3.1.3. Vision Care Devices
      • 4.3.1.3.1. Vision Care Devices Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 4.3.2. Drugs
      • 4.3.2.1. Drugs Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
      • 4.3.2.2. OTC Drugs
      • 4.3.2.2.1. OTC Drugs Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
      • 4.3.2.3. Prescription Drugs
      • 4.3.2.3.1. Prescription Drugs Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)

Chapter 5. Ophthalmic Clinical Trials Market: Indication Estimates & Trend Analysis

  • 5.1. Ophthalmic Clinical Trials Market, By Indication: Segment Dashboard
  • 5.2. Ophthalmic Clinical Trials Market, By Indication: Movement Analysis
  • 5.3. Ophthalmic Clinical Trials Market Estimates & Forecasts, By Indication, 2018 - 2030
    • 5.3.1. Macular Degeneration
      • 5.3.1.1. Macular Degeneration Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.2. Glaucoma
      • 5.3.2.1. Glaucoma Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.3. Dry Eye Disease
      • 5.3.3.1. Dry Eye Disease Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.4. Retinopathy
      • 5.3.4.1. Retinopathy Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.5. Uveitis
      • 5.3.5.1. Uveitis Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.6. Macular Edema
      • 5.3.6.1. Macular Edema Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.7. Blepharitis
      • 5.3.7.1. Blepharitis Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.8. Cataract
      • 5.3.8.1. Cataract Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.9. Optic Neuropathy
      • 5.3.9.1. Optic Neuropathy Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.10. Others
      • 5.3.10.1. Others Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)

Chapter 6. Ophthalmic Clinical Trials Market: Phase Estimates & Trend Analysis

  • 6.1. Ophthalmic Clinical Trials Market, By Phase: Segment Dashboard
  • 6.2. Ophthalmic Clinical Trials Market, By Phase: Movement Analysis
  • 6.3. Ophthalmic Clinical Trials Market Estimates & Forecasts, By Phase, 2018 - 2030
    • 6.3.1. Discovery Phase
      • 6.3.1.1. Discovery Phase Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)
    • 6.3.2. Preclinical Phase
      • 6.3.2.1. Preclinical Phase Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)
    • 6.3.3. Clinical Phase
      • 6.3.3.1. Clinical Phase Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)

Chapter 7. Ophthalmic Clinical Trials Market: Sponsor Type Estimates & Trend Analysis

  • 7.1. Ophthalmic Clinical Trials Market, By Sponsor Type: Segment Dashboard
  • 7.2. Ophthalmic Clinical Trials Market, By Sponsor Type: Movement Analysis
  • 7.3. Ophthalmic Clinical Trials Market Estimates & Forecasts, By Phase, 2018 - 2030
    • 7.3.1. Pharmaceutical/biopharmaceutical Companies
      • 7.3.1.1. Pharmaceutical/biopharmaceutical Companies Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)
    • 7.3.2. Medical Device Companies
      • 7.3.2.1. Medical Device Companies Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)
    • 7.3.3. Others
      • 7.3.3.1. Others Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)

Chapter 8. Ophthalmic Clinical Trials Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2022 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. North America
    • 8.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 8.5. Europe
    • 8.5.1. UK
      • 8.5.1.1. Key Country Dynamics
      • 8.5.1.2. Competitive Scenario
      • 8.5.1.3. Regulatory Framework
      • 8.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 8.5.2. Germany
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 8.5.3. France
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 8.5.4. Italy
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 8.5.5. Spain
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 8.5.6. Denmark
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 8.5.7. Sweden
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 8.5.8. Norway
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
  • 8.6. Asia Pacific
    • 8.6.1. Japan
      • 8.6.1.1. Key Country Dynamics
      • 8.6.1.2. Competitive Scenario
      • 8.6.1.3. Regulatory Framework
      • 8.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 8.6.2. India
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    • 8.6.4. South Korea
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 8.6.6. Thailand
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 8.7. Latin America
    • 8.7.1. Brazil
      • 8.7.1.1. Key Country Dynamics
      • 8.7.1.2. Competitive Scenario
      • 8.7.1.3. Regulatory Framework
      • 8.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 8.7.2. Mexico
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
  • 8.8. MEA
    • 8.8.1. South Africa
      • 8.8.1.1. Key Country Dynamics
      • 8.8.1.2. Competitive Scenario
      • 8.8.1.3. Regulatory Framework
      • 8.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 8.8.2. Saudi Arabia
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 8.8.3. UAE
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 8.8.4. Kuwait
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
    • 9.1.1. Innovators
    • 9.1.2. Market Leaders
    • 9.1.3. Emerging Players
    • 9.1.4. Company Market Share Analysis, 2022
  • 9.2. Company Profiles
    • 9.2.1. Charles River Laboratories International, Inc
      • 9.2.1.1. Company Overview
      • 9.2.1.2. Financial Performance
      • 9.2.1.3. Service Benchmarking
      • 9.2.1.4. Strategic Initiatives
    • 9.2.2. Laboratory Corporation of America Holdings
      • 9.2.2.1. Company Overview
      • 9.2.2.2. Financial Performance
      • 9.2.2.3. Service Benchmarking
      • 9.2.2.4. Strategic Initiatives
    • 9.2.3. IQVIA
      • 9.2.3.1. Company Overview
      • 9.2.3.2. Financial Performance
      • 9.2.3.3. Service Benchmarking
      • 9.2.3.4. Strategic Initiatives
    • 9.2.4. ICON Plc
      • 9.2.4.1. Company Overview
      • 9.2.4.2. Financial Performance
      • 9.2.4.3. Service Benchmarking
      • 9.2.4.4. Strategic Initiatives
    • 9.2.5. Vial
      • 9.2.5.1. Company Overview
      • 9.2.5.2. Financial Performance
      • 9.2.5.3. Service Benchmarking
      • 9.2.5.4. Strategic Initiatives
    • 9.2.6. Medpace
      • 9.2.6.1. Company Overview
      • 9.2.6.2. Financial Performance
      • 9.2.6.3. Service Benchmarking
      • 9.2.6.4. Strategic Initiatives
    • 9.2.7. ProTrials Research, Inc.
      • 9.2.7.1. Company Overview
      • 9.2.7.2. Financial Performance
      • 9.2.7.3. Service Benchmarking
      • 9.2.7.4. Strategic Initiatives
    • 9.2.8. Syneos Health
      • 9.2.8.1. Company Overview
      • 9.2.8.2. Financial Performance
      • 9.2.8.3. Service Benchmarking
      • 9.2.8.4. Strategic Initiatives
    • 9.2.9. Worldwide Clinical Trials, Inc
      • 9.2.9.1. Company Overview
      • 9.2.9.2. Financial Performance
      • 9.2.9.3. Service Benchmarking
      • 9.2.9.4. Strategic Initiatives
    • 9.2.10. ProRelix Services LLP.
      • 9.2.10.1. Company Overview
      • 9.2.10.2. Financial Performance
      • 9.2.10.3. Service Benchmarking
      • 9.2.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 North America Ophthalmic Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 4 North America Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 5 North America Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 6 North America Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 7 North America Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 8 U.S. Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 9 U.S. Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 10 U.S. Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 11 U.S. Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 12 Canada Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 13 Canada Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 14 Canada Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 15 Canada Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 16 Europe Ophthalmic Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 17 Europe Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 18 Europe Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 19 Europe Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 20 Europe Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 21 UK Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 22 UK Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 23 UK Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 24 UK Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 25 Germany Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 26 Germany Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 27 Germany Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 28 Germany Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 29 France Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 30 France Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 31 France Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 32 France Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 33 Italy Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 34 Italy Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 35 Italy Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 36 Italy Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 37 Spain Ophthalmic Clinical Trials market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 38 Spain Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 39 Spain Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 40 Spain Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 41 Denmark Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 42 Denmark Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 43 Denmark Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 44 Denmark Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 45 Sweden Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 46 Sweden Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 47 Sweden Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 48 Sweden Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 49 Norway Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 50 Norway Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 51 Norway Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 52 Norway Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 53 Asia Pacific Ophthalmic Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 58 China Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 59 China Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 60 China Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 61 China Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 62 Japan Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 63 Japan Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 64 Japan Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 65 Japan Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 66 India Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 67 India Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 68 India Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 69 India Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 70 Australia Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 71 Australia Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 72 Australia Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 73 Australia Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 74 South Korea Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 75 South Korea Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 76 South Korea Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 77 South Korea Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 78 Thailand Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 79 Thailand Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 80 Thailand Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 81 Thailand Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 82 Latin America Ophthalmic Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 83 Latin America Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 84 Latin America Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 85 Latin America Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 86 Latin America Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 87 Brazil Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 88 Brazil Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 89 Brazil Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 90 Brazil Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 91 Mexico Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 92 Mexico Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 93 Mexico Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 94 Mexico Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 95 Argentina Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 96 Argentina Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 97 Argentina Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 98 Argentina Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 99 Middle East and Africa Ophthalmic Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 100 Middle East and Africa Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 101 Middle East and Africa Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 102 Middle East and Africa Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 103 Middle East and Africa Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 104 South Africa Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 105 South Africa Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 106 South Africa Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 107 South Africa Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 111 South Arabia Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 112 UAE Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 113 UAE Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 114 UAE Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 115 UAE Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 116 Kuwait Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 117 Kuwait Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 118 Kuwait Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 119 Kuwait Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modelling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Primary research pattern
  • Fig. 8 Primary interviews in North America
  • Fig. 9 Primary interviews in Europe
  • Fig. 10 Primary interviews in Asia Pacific
  • Fig. 11 Primary interviews in Latin America
  • Fig. 12 Primary interviews in MEA
  • Fig. 13 Market Snapshot
  • Fig. 14 Segment Snapshot
  • Fig. 15 Segment Snapshot
  • Fig. 16 Competitive Landscape Snapshot
  • Fig. 17 Ophthalmic Clinical Trials market segmentation
  • Fig. 18 Parent market outlook (2022)
  • Fig. 19 Related/ancillary market outlook (2022)
  • Fig. 20 Market driver relevance analysis (Current & future impact)
  • Fig. 21 Current shared services and outsourcing usage levels
  • Fig. 22 Market restraint relevance analysis (Current & future impact)
  • Fig. 23 Porter's five forces analysis
  • Fig. 24 SWOT analysis, by a factor (political & legal, economic and technological)
  • Fig. 25 Ophthalmic Clinical Trials Market Product outlook: Segment dashboard
  • Fig. 26 Ophthalmic Clinical Trials : Product movement analysis
  • Fig. 27 Devices market, 2018 - 2030 (USD Million)
  • Fig. 28 Drugs market, 2018 - 2030 (USD Million)
  • Fig. 29 Ophthalmic Clinical Trials Market Indication outlook: Segment dashboard
  • Fig. 30 Ophthalmic Clinical Trials : Indication movement analysis
  • Fig. 31 Macular Degeneration market, 2018 - 2030 (USD Million)
  • Fig. 32 Glaucoma market, 2018 - 2030 (USD Million)
  • Fig. 33 Dry eye diseases market, 2018 - 2030 (USD Million)
  • Fig. 34 Retinopathy market, 2018 - 2030 (USD Million)
  • Fig. 35 Uveitis market, 2018 - 2030 (USD Million)
  • Fig. 36 Macular Edema market, 2018 - 2030 (USD Million)
  • Fig. 37 Blepharitis market, 2018 - 2030 (USD Million)
  • Fig. 38 Cataract market, 2018 - 2030 (USD Million)
  • Fig. 39 Optic neuropathy market, 2018 - 2030 (USD Million)
  • Fig. 40 Others market, 2018 - 2030 (USD Million)
  • Fig. 41 Ophthalmic Clinical Trials market Phase outlook: Segment dashboard
  • Fig. 42 Ophthalmic Clinical Trials market: Phase movement analysis
  • Fig. 43 Discovery phase market, 2018 - 2030 (USD Million)
  • Fig. 44 Preclinical phase market, 2018 - 2030 (USD Million)
  • Fig. 45 Clinical phase market, 2018 - 2030 (USD Million)
  • Fig. 46 Ophthalmic Clinical Trials market Sponsor type outlook: Segment dashboard
  • Fig. 47 Ophthalmic Clinical Trials market: Sponsor type movement analysis
  • Fig. 48 Pharmaceutical/ Biopharmaceutical Companies market, 2018 - 2030 (USD Million)
  • Fig. 49 Medical device companies market, 2018 - 2030 (USD Million)
  • Fig. 50 Others market, 2018 - 2030 (USD Million)
  • Fig. 51 Regional marketplace: Segment dashboard
  • Fig. 52 Regional outlook, 2022 & 2030
  • Fig. 53 North America market, 2018 - 2030 (USD Million)
  • Fig. 54 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 55 Canada market, 2018 - 2030 (USD Million)
  • Fig. 56 Europe market, 2018 - 2030 (USD Million)
  • Fig. 57 Germany market, 2018 - 2030 (USD Million)
  • Fig. 58 UK market, 2018 - 2030 (USD Million)
  • Fig. 59 France market, 2018 - 2030 (USD Million)
  • Fig. 60 Italy market, 2018 - 2030 (USD Million)
  • Fig. 61 Spain market, 2018 - 2030 (USD Million)
  • Fig. 62 Denmark market, 2018 - 2030(USD Million)
  • Fig. 63 Sweden market, 2018 - 2030 (USD Million)
  • Fig. 64 Norway market, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 66 China market, 2018 - 2030 (USD Million)
  • Fig. 67 Japan market, 2018 - 2030 (USD Million)
  • Fig. 68 India market, 2018 - 2030 (USD Million)
  • Fig. 69 Australia market, 2018 - 2030 (USD Million)
  • Fig. 70 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 71 Thailand Markey, 2018 - 2030 (USD Million)
  • Fig. 71 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 72 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 73 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 74 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 75 Middle East & Africa market, 2018 - 2030 (USD Million)
  • Fig. 76 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 77 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 78 UAE market, 2018 - 2030 (USD Million)
  • Fig. 79 Kuwait market, 2018 - 2030 (USD Million)